513 related articles for article (PubMed ID: 32720318)
1. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
2. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
[TBL] [Abstract][Full Text] [Related]
3. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
[TBL] [Abstract][Full Text] [Related]
7. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
Furlanetto J; Möbus V; Schneeweiss A; Rhiem K; Tesch H; Blohmer JU; Lübbe K; Untch M; Salat C; Huober J; Klare P; Schmutzler R; Couch FJ; Lederer B; Gerber B; Zahm DM; Bauerfeind I; Nekljudova V; Hanusch C; Jackisch C; Link T; Hahnen E; Loibl S; Fasching PA
Eur J Cancer; 2021 Mar; 145():44-52. PubMed ID: 33423006
[TBL] [Abstract][Full Text] [Related]
8. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
Fasching PA; Loibl S; Hu C; Hart SN; Shimelis H; Moore R; Schem C; Tesch H; Untch M; Hilfrich J; Rezai M; Gerber B; Costa SD; Blohmer JU; Fehm T; Huober J; Liedtke C; Weinshilboum RM; Wang L; Ingle JN; Müller V; Nekljudova V; Weber KE; Rack B; Rübner M; von Minckwitz G; Couch FJ
J Clin Oncol; 2018 Aug; 36(22):2281-2287. PubMed ID: 29791287
[TBL] [Abstract][Full Text] [Related]
9. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Sharma P; López-Tarruella S; García-Saenz JA; Khan QJ; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Monte-Millán MD; González-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortés J; Fuentes-Rivera H; Morales DB; Márquez-Rodas I; Perou CM; Lehn C; Wang YY; Klemp JR; Mammen JV; Wagner JL; Amin AL; O'Dea AP; Heldstab J; Jensen RA; Kimler BF; Godwin AK; Martín M
Clin Cancer Res; 2018 Dec; 24(23):5820-5829. PubMed ID: 30061361
[TBL] [Abstract][Full Text] [Related]
10. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
11. The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
Mutai R; Kuchuk I; Goldshtein A; Yerushalmi R; Rotem O; Maisel Lotan A; Bdolah-Abram T; Gabizon A; Goldvaser H
Breast Cancer Res Treat; 2024 Jun; 205(2):241-248. PubMed ID: 38345692
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
13. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
14. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
González-Rivera M; Lobo M; López-Tarruella S; Jerez Y; Del Monte-Millán M; Massarrah T; Ramos-Medina R; Ocaña I; Picornell A; Santillán Garzón S; Pérez-Carbornero L; García-Saenz JA; Gómez H; Moreno F; Márquez-Rodas I; Fuentes H; Martin M
Breast Cancer Res Treat; 2016 Apr; 156(3):507-515. PubMed ID: 27083178
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Sci; 2018 Jan; 109(1):166-173. PubMed ID: 29047188
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
Sheng S; Xu Y; Guo Y; Yao L; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jan; 146(2):487-495. PubMed ID: 31119730
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Telli ML; Jensen KC; Vinayak S; Kurian AW; Lipson JA; Flaherty PJ; Timms K; Abkevich V; Schackmann EA; Wapnir IL; Carlson RW; Chang PJ; Sparano JA; Head B; Goldstein LJ; Haley B; Dakhil SR; Reid JE; Hartman AR; Manola J; Ford JM
J Clin Oncol; 2015 Jun; 33(17):1895-901. PubMed ID: 25847929
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
Wang C; Zhang J; Wang Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2015 Mar; 26(3):523-8. PubMed ID: 25480878
[TBL] [Abstract][Full Text] [Related]
19. A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer.
Hamm C; Fifield BA; Kay A; Kulkarni S; Gupta R; Mathews J; Ferraiuolo RM; Al-Wahsh H; Mailloux E; Hussein A; Porter LA
Med Oncol; 2022 Feb; 39(4):49. PubMed ID: 35103812
[TBL] [Abstract][Full Text] [Related]
20. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T; Guiu S; Van Praagh I; Jouannaud C; Dubray-Longeras P; Tubiana-Mathieu N; Benmammar KE; Kullab S; Bahadoor MR; Radosevic-Robin N; Kwiatkowski F; Desrichard A; Cayre A; Uhrhammer N; Chalabi N; Chollet P; Penault-Llorca F
Ann Oncol; 2014 Aug; 25(8):1570-7. PubMed ID: 24827135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
